New cancer prevention strategies like the human papillomavirus (HPV) vaccine are making waves throughout the United States and around the world. Evidence has shown that the vaccine can help protect against certain cancers such as cervical, anal, oropharyngeal, penile, vulvar, and vaginal in people who receive the vaccine. For the first time ever, the World Health Organization (WHO) has global data outlining HPV coverage in countries across the globe.  

Recent congressional hearings about vaccination have caused a litany of responses from different members of the public, private, and political sectors. Current Centers for Disease Control and Prevention (CDC) evidence has shown that human papillomavirus (HPV) vaccination has led to fewer cases of HPV-related cancers.  

Not that long ago, women were told to get a Pap test every year. And most of us did, even though it wasn’t always clear why we were being tested. We just did what we were told and thought it was a surefire way to stay healthy. But times and recommendations have changed about what test to have, how often to have it, and the reason to have it. 

An S5 methylation test detected 100% of grade 2 cervical intraepithelial neoplasms or worse, compared to a 50% detection rate for Pap or human papillomavirus (HPV) tests, according to the results of a recent study reported in the International Journal of Cancer.

Pap tests have long been the gold standard to screen women for cervical cancer, but a new study published in JAMA says that in women older than 30 years, HPV testing is less invasive and more accurate.  

January was cervical health awareness month, and the federal government, along with many advocacy groups, spent considerable time talking about early detection. According to the National Cancer Institute and the U.S. Food and Drug Administration (FDA), cervical cancer is largely preventable. If it’s detected early, it’s often curable too. Many experts say that the key to cervical cancer is vaccination and embracing the two tests used for early detection—Pap smears and human papillomavirus (HPV) testing.

A new genetic test that analyzes multiple sources of DNA may be able to detect high-risk cervical cancer more accurately than other available tests: it showed 90.9% sensitivity in identifying cervical intraepithelial neoplasia 2 lesions. The findings from the proof-of-concept study were reported in Cancer Prevention Research.